Matthew J Maurice1, Hui Zhu2, Simon Kim3, Robert Abouassaly3. 1. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States. 2. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States;; Division of Urology, Louis Stoke Cleveland VA Medical Center, Cleveland, OH, United States. 3. Urology Institute, University Hospitals Case Medical Center, Cleveland, OH, United States.
Abstract
INTRODUCTION: Increasingly, partial nephrectomy has been applied to high-risk disease without evidence that its survival benefits can be extrapolated to this entity. We aimed to compare overall survival after partial vs. radical nephrectomy in patients with high-risk renal cell carcinoma. METHODS: Using the National Cancer Data Base, we identified patients who underwent partial or radical nephrectomy for high-risk disease between 2003 and 2006. High-risk disease was defined as the presence of adverse pathological features within the primary tumour, namely high-grade or unfavourable histology, T3 stage, or both. After matching the partial and radical nephrectomy groups based on propensity scores, 1680, 276, and 76 patients with high-grade or unfavourable histology, T3 stage, or both adverse pathologic features, respectively, were available for analysis. Five-year overall survival was compared after partial vs. radical nephrectomy for each high-risk cohort using the Kaplan-Meier and log rank tests. RESULTS: Partial nephrectomy was associated with a statistically significant improvement in five-year overall survival compared to radical nephrectomy for small tumours (median size 3.0 cm; interquartile range 2.1-4.5 cm) with high-grade or unfavourable histology (87% vs. 81%; p<0.01) or with pT3a stage (82% vs. 71%; p<0.01). For patients concomitantly harbouring both adverse pathologic features, no difference in survival was detected (p=0.21). CONCLUSIONS: Partial nephrectomy is associated with survival benefits in patients with adverse pathologic features, suggesting that renal preservation is not only safe, but also potentially beneficial for high-risk disease. Due to inherent selection bias associated with partial nephrectomy use, prospective validation of these findings is needed.
INTRODUCTION: Increasingly, partial nephrectomy has been applied to high-risk disease without evidence that its survival benefits can be extrapolated to this entity. We aimed to compare overall survival after partial vs. radical nephrectomy in patients with high-risk renal cell carcinoma. METHODS: Using the National Cancer Data Base, we identified patients who underwent partial or radical nephrectomy for high-risk disease between 2003 and 2006. High-risk disease was defined as the presence of adverse pathological features within the primary tumour, namely high-grade or unfavourable histology, T3 stage, or both. After matching the partial and radical nephrectomy groups based on propensity scores, 1680, 276, and 76 patients with high-grade or unfavourable histology, T3 stage, or both adverse pathologic features, respectively, were available for analysis. Five-year overall survival was compared after partial vs. radical nephrectomy for each high-risk cohort using the Kaplan-Meier and log rank tests. RESULTS: Partial nephrectomy was associated with a statistically significant improvement in five-year overall survival compared to radical nephrectomy for small tumours (median size 3.0 cm; interquartile range 2.1-4.5 cm) with high-grade or unfavourable histology (87% vs. 81%; p<0.01) or with pT3a stage (82% vs. 71%; p<0.01). For patients concomitantly harbouring both adverse pathologic features, no difference in survival was detected (p=0.21). CONCLUSIONS: Partial nephrectomy is associated with survival benefits in patients with adverse pathologic features, suggesting that renal preservation is not only safe, but also potentially beneficial for high-risk disease. Due to inherent selection bias associated with partial nephrectomy use, prospective validation of these findings is needed.
Authors: Christopher J Weight; Benjamin T Larson; Tianming Gao; Steven C Campbell; Brian R Lane; Jihad H Kaouk; Inderbir S Gill; Eric A Klein; Amr F Fergany Journal: Urology Date: 2010-05-10 Impact factor: 2.649
Authors: Christopher J Weight; Casey Lythgoe; Raman Unnikrishnan; Brian R Lane; Steven C Campbell; Amr F Fergany Journal: Urology Date: 2011-03-21 Impact factor: 2.649
Authors: Jens Hansen; Maxine Sun; Marco Bianchi; Michael Rink; Zhe Tian; Nawar Hanna; Malek Meskawi; Jan Schmitges; Shahrokh F Shariat; Felix K-H Chun; Paul Perrotte; Markus Graefen; Pierre I Karakiewicz Journal: Urology Date: 2012-06-13 Impact factor: 2.649
Authors: Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2012-06-13 Impact factor: 7.450
Authors: Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Claudio Jeldres; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Ann Surg Oncol Date: 2012-02-10 Impact factor: 5.344
Authors: Rodney H Breau; Paul L Crispen; Rafael E Jimenez; Christine M Lohse; Michael L Blute; Bradley C Leibovich Journal: J Urol Date: 2010-01-18 Impact factor: 7.450